FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting
{{output}}
Context: Metastatic urothelial cancer (mUC) is associated with diverse genomic alterations, including frequent FGFR3 mutations that influence survival outcomes and treatment responses. Erdafitinib, a targeted therapy, has shown i... ...
